Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$-0.04
Change (1 day)
$7.95
Year High
$4.91
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 847.5 M | -2,855,546,532 | 380.09 M | 6.05 B | 4.32 B |
| 2022 | 1.15 B | -1,899,588,966 | 544.54 M | 5.85 B | 4.27 B |
| 2021 | 950.97 M | -1,862,062,967 | 510.36 M | 5.42 B | 4.17 B |
| 2020 | 1.13 B | -1,271,343,177 | 544.64 M | 4.8 B | 3.87 B |
| 2019 | 750.78 M | -638,746,542 | 361.79 M | 3.81 B | 3.08 B |